ESTRO 2024 - Abstract Book

S1870

Clinical - Mixed sites, palliation

ESTRO 2024

different

cancer

types

are

required.

Keywords: Psychooncology, health literacy

References:

[1] Haun MW, Schakowski A, Preibsch A, Friederich HC, Hartmann M. Assessing decision regret in caregivers of deceased German people with cancer-A psychometric validation of the Decision Regret Scale for Caregivers. Health Expect. 2019;22:1089-99.

[2] Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L. Validation of a decision regret scale. Med Decis Making. 2003; 4:281-92.

959

Digital Poster

Whole brain radiotherapy for palliative patients: Are we doing our best?

Charlotte Kristiansen 1,2 , Julie Stougaard 1 , Rune Slot Thing 2 , Henrik Dahl Nissen 2 , Martin Berg 2 , Christine Vestergaard Madsen 1,2 , Lars Fokdal 1,2 1 Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark. 2 Radiotherapy Research Team, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark

Purpose/Objective:

Due to an aging population an increasing number of cancer patients are expected. Moreover, patients will live longer with their disease due to improvements in systemic therapy. As a consequence, there is an increased risk of developing brain metastases in older patients. Systemic treatment in particular immunotherapy and targeted treatments is an option for treatment of brain metastases, due to new generation drugs’ ability to cross the blood brain barrier; despite this, many patients are still referred for whole brain radiotherapy (RT). Whole brain radiotherapy is considered a palliative treatment for patients for whom systemic treatment has failed, and they are not candidates for stereotactic radiosurgery or surgery. Generally, a RT treatment schedule with 10 fractions is used for well performing patients, while 4-5 fractions are used for more frail patients who are expected to have a short overall survival. This study aims to look into our practice with regard to dose prescription of palliative whole brain RT for cancer patients with brain metastases as well as to look into the cancer diagnosis, age and RT schedule prescribed.

Material/Methods:

The present study includes a retrospective analysis of our practice for palliative whole brain RT in the period from January 2018 to December 2022. Age, diagnose code, radiotherapy schedule with dose/fractionation (20Gy/4F, 20Gy/5F and 30Gy/10F), follow- up time, and survival status was extracted from the department’s database and analysed descriptively. Survival was analysed with Kaplan-Meier statistics. Comparisons of time to event in